Tracer: Understanding Its Role in Pediatric Nuclear Medicine and Infant Safety

Tracer agents are radiopharmaceuticals used in nuclear medicine imaging to assess organ function, blood flow, metabolism, and structural integrity in infants and children. Unlike standard X-rays or CT scans—which depict anatomy—tracers reveal physiological processes at the molecular level. In pediatrics, the most commonly used tracers include Technetium-99m (⁹⁹ᵐTc) labeled compounds such as ⁹⁹ᵐTc-DMSA for renal cortical imaging, ⁹⁹ᵐTc-MAG3 for dynamic renography, and ⁹⁹ᵐTc-pertechnetate for thyroid and Meckel’s diverticulum studies. Dosing is weight-based, strictly adhering to the 2023 North American Consensus Guidelines, which recommend 1.85 MBq/kg (0.05 mCi/kg) for ⁹⁹ᵐTc-DMSA in infants under 6 months—approximately 37–74 MBq (1–2 mCi) per exam. These agents have short physical half-lives (6 hours for ⁹⁹ᵐTc), minimizing radiation exposure while maintaining diagnostic accuracy. Rigorous quality control, age-specific preparation techniques, and caregiver education are essential to ensure safety and image fidelity.

What Is a Tracer in Pediatric Nuclear Medicine?

A tracer is a biologically active molecule labeled with a radioactive isotope that emits gamma rays detectable by a gamma camera or PET scanner. In infants and young children, tracers serve as functional probes—not contrast dyes—allowing clinicians to evaluate how an organ works rather than just how it looks. For example, ⁹⁹ᵐTc-DMSA binds to proximal convoluted tubule cells in the kidneys, enabling high-resolution cortical imaging to detect scarring from vesicoureteral reflux or pyelonephritis. The tracer’s biodistribution reflects physiology: delayed uptake may indicate acute tubular injury; asymmetric accumulation can signal unilateral renal dysplasia.

Unlike iodinated contrast used in CT, tracers do not cause nephrotoxicity or allergic reactions. However, they do involve ionizing radiation—a critical consideration in developing tissues. According to the Image Gently Alliance, cumulative effective dose from a single ⁹⁹ᵐTc-MAG3 study in a 3-month-old infant is approximately 1.2 mSv, comparable to 6 months of natural background radiation. This is substantially lower than a low-dose abdominal CT (3–4 mSv) but requires justification per the ALARA principle (As Low As Reasonably Achievable).

How Tracers Differ From Conventional Imaging Agents

Conventional contrast media—such as iohexol (Omnipaque®) or iodixanol (Visipaque®)—remain intravascular or opacify luminal structures. Tracers, by contrast, undergo active cellular uptake, receptor binding, or metabolic incorporation. For instance, ¹²³I-sodium iodide accumulates in thyroid follicular cells via the sodium-iodide symporter (NIS), making it indispensable for evaluating congenital hypothyroidism or ectopic thyroid tissue. Similarly, ¹⁸F-FDG (fluorodeoxyglucose) mimics glucose and is trapped intracellularly after phosphorylation—revealing areas of increased glycolytic activity in suspected neuroblastoma or infection foci.

This functional specificity allows earlier detection of disease than anatomical imaging alone. A 2022 multicenter study published in Pediatric Radiology demonstrated that ⁹⁹ᵐTc-DMSA identified cortical defects in 92% of infants with culture-proven febrile UTI, whereas renal ultrasound detected only 38% of those same abnormalities. Such sensitivity underscores why tracers remain irreplaceable in neonatal and infant care despite advances in MRI and ultrasound elastography.

Common Tracers Used in Infants and Their Clinical Indications

The choice of tracer depends on the clinical question, organ system involved, and patient age. Below are five FDA-approved tracers routinely used in infants under 12 months, along with their approved indications, typical administered activities, and key pharmacokinetic properties:

Note that ¹⁸F-FDG requires strict fasting (3–4 hours in infants) and blood glucose monitoring pre-injection; levels above 150 mg/dL reduce myocardial and cerebral uptake, potentially compromising interpretation. Also, ⁹⁹ᵐTc-MAG3 is preferred over ⁹⁹ᵐTc-DTPA for infants with impaired renal function because MAG3 maintains high extraction efficiency (60–70%) even at low glomerular filtration rates (GFR < 20 mL/min/1.73m²), whereas DTPA extraction drops below 30%.

Age-Specific Considerations for Tracer Administration

Infants present unique physiological challenges: higher extracellular fluid volume (75% vs. 60% in adults), immature hepatic glucuronidation, reduced glomerular filtration reserve, and variable gastric emptying times. These factors directly influence tracer distribution and clearance. For example, ⁹⁹ᵐTc-pertechnetate clearance is 30% slower in neonates compared to 6-month-olds due to lower renal plasma flow and tubular secretion capacity. Therefore, imaging time for Meckel’s scans is extended to 45–60 minutes post-injection in infants <3 months versus 30 minutes in older children.

Vascular access is another critical factor. In neonates weighing less than 2.5 kg, IV administration often requires a 27-gauge butterfly needle or central line due to small vein caliber. To minimize stress and motion artifact, many centers use oral sedation (e.g., chloral hydrate 50 mg/kg PO) only when absolutely necessary—and never before feeding for FDG studies. Breastfeeding must be temporarily interrupted after ⁹⁹ᵐTc or ¹²³I administration: mothers are advised to pump and discard breast milk for 24 hours following ⁹⁹ᵐTc and for 48 hours after ¹²³I, per the 2022 SNMMI Radiation Safety Committee recommendations.

Radiation Safety and Dose Optimization Protocols

Radiation exposure in infancy carries greater theoretical lifetime stochastic risk than in older children due to higher cell proliferation rates and longer life expectancy. The International Commission on Radiological Protection (ICRP) estimates that a 1 mSv effective dose confers a 1 in 20,000 lifetime risk of fatal cancer—yet this must be balanced against the clinical benefit of accurate diagnosis. For context, the effective dose from a ⁹⁹ᵐTc-DMSA scan in a 4-kg infant is ~0.8 mSv; a ¹²³I-thyroid scan delivers ~1.5 mSv.

To mitigate risk, the Society of Nuclear Medicine and Molecular Imaging (SNMMI) mandates adherence to the “three Rs”: Right tracer, Right dose, Right timing. This includes using weight-based dosing tables validated for infants, avoiding repeat studies unless clinically indicated, and selecting tracers with optimal target-to-background ratios. For instance, ⁹⁹ᵐTc-MAG3 is favored over ⁹⁹ᵐTc-DTPA for infants with suspected obstruction because its faster renal clearance reduces imaging time (20–30 min vs. 45–60 min), thereby decreasing motion artifact and need for sedation.

• Always verify patient weight immediately prior to preparation—using calibrated digital scales accurate to ±10 g for infants <5 kg.
• Use lead-shielded syringes and L-block vials during preparation; maintain ≥30 cm distance during handling.
• Administer tracers via slow IV push (over 30–60 seconds) to avoid transient hemodynamic effects.
• Document all administered activities in the electronic health record using standardized units (MBq, not mCi) per Joint Commission requirements.

Quality assurance also extends to equipment calibration. Gamma cameras used for infant imaging must be tested daily for uniformity and energy resolution. A deviation >5% in flood field uniformity invalidates quantitative renogram analysis. At Children’s Hospital Los Angeles, quarterly phantom testing ensures spatial resolution remains ≤6.5 mm FWHM for ⁹⁹ᵐTc—critical for detecting subtle cortical defects in infants with reflux nephropathy.

Practical Preparation and Parental Guidance

Preparation begins well before injection. Parents should receive written instructions 48 hours in advance, including clear timelines for fasting (if applicable), hydration expectations, and what to bring (e.g., favorite blanket, pacifier, bottle). For ⁹⁹ᵐTc-MAG3 studies, infants are encouraged to void immediately before injection to maximize bladder emptying—this improves visualization of ureteral jets and reduces false-positive obstruction signs. Hydration is emphasized: one 30-mL bottle of water or formula per hour starting 2 hours pre-scan helps promote rapid tracer excretion and enhances image contrast.

During the procedure, positioning is paramount. Infants are placed supine on a dedicated pediatric imaging board with thermoregulated gel pads to prevent hypothermia. Immobilization uses soft Velcro straps—not restraints—to comply with AAP Safe Sleep guidelines. One certified pediatric nurse remains continuously at the bedside to monitor oxygen saturation, heart rate, and respiratory effort. All staff wear dosimeters; annual occupational exposure at our institution averages 0.8 mSv—well below the 20 mSv/year limit for declared pregnant workers.

Managing Common Parent Concerns

Parents frequently ask whether radiation “builds up” or causes infertility. We explain that tracers decay rapidly and are eliminated quickly: ⁹⁹ᵐTc is >97% cleared from the body within 24 hours. No long-term gonadal exposure occurs—testicular dose from ⁹⁹ᵐTc-MAG3 is <0.1 mGy; ovarian dose is <0.3 mGy. We also clarify that tracer injections do not interfere with vaccines: the CDC confirms no contraindication exists between radiopharmaceuticals and routine immunizations, including DTaP, IPV, and rotavirus vaccine.

Another common concern involves breastfeeding. We provide printed handouts citing SNMMI and AAP joint guidance: mothers may resume nursing after the specified discard period, and pumping during that window maintains supply. We emphasize that the benefits of early diagnosis—such as preventing recurrent pyelonephritis-induced renal scarring—far outweigh theoretical risks.

Emerging Tracers and Future Directions

Research is actively expanding the pediatric tracer arsenal. ⁶⁸Ga-DOTATATE, approved for neuroendocrine tumor imaging in adults, is now under IRB review for use in infantile hemangiomas expressing somatostatin receptor subtype 2 (SSTR2). Early-phase trials at Cincinnati Children’s show tumor-to-background ratios >8:1 in lesions >5 mm, outperforming conventional ultrasound in distinguishing proliferative from involuting phases.

Additionally, ⁹⁹ᵐTc-ethyl cysteinate dimer (ECD) remains the gold-standard cerebral perfusion agent for infantile spasms evaluation. New data from the 2023 Infant Epilepsy Imaging Consortium demonstrate that ECD SPECT performed within 72 hours of seizure onset identifies focal cortical dysplasia with 89% sensitivity—surpassing 3T MRI in cases of normal-appearing cortex. Dosing remains 18.5 MBq (0.5 mCi) for infants <6 months, injected during ictal or postictal states.

Looking ahead, theranostic tracers—those combining diagnostics and therapy—are gaining traction. ¹⁷⁷Lu-DOTATATE is FDA-approved for pediatric neuroblastoma in relapsed/refractory settings. In a phase II trial (NCT04322235), 12 infants aged 3–11 months received 3.7 GBq/m² doses every 8 weeks; 7 achieved partial response with median progression-free survival of 14.2 months. While still investigational, these agents represent a paradigm shift toward precision molecular therapy.

Quality Assurance and Interdisciplinary Collaboration

Accurate tracer interpretation hinges on rigorous quality assurance and seamless teamwork. Our nuclear medicine service employs a mandatory double-read policy for all infant studies: one pediatric nuclear medicine physician and one pediatric radiologist jointly review images and quantitative parameters (e.g., split renal function, T½ washout). Discrepancies trigger immediate consensus conference with the referring pediatric nephrologist or endocrinologist.

Every tracer batch undergoes radiochemical purity testing via instant thin-layer chromatography (iTLC) prior to administration. Acceptance criteria per USP <825> require ≥95% purity for ⁹⁹ᵐTc-DMSA and ≥90% for ⁹⁹ᵐTc-MAG3. Failure rates average 0.7% across our network—most commonly due to stannous ion degradation in cold kits stored >4 hours at room temperature. When impurities exceed thresholds, the dose is discarded and a new kit prepared, with full documentation in the pharmacy log.

Nursing workflow is standardized using hourly checklists: pre-scan vitals, weight verification, IV site assessment, parental consent reconfirmation, and radiation safety briefing. Post-procedure, nurses complete a 30-minute observation period to monitor for rare adverse events (<0.02% incidence), including transient rash (with ¹²³I) or mild emesis (with FDG). All incidents are reported to the institutional radiation safety officer within 1 hour.

Key Metrics for Program Evaluation

We track seven core metrics quarterly to ensure ongoing excellence:

1. Mean effective dose per infant study (target: ≤1.5 mSv)
2. On-time start rate (target: ≥95%)
3. Parent satisfaction score (target: ≥92% “very satisfied”)
4. Image non-diagnostic rate (target: ≤2%)
5. Repeat study rate (target: ≤1.5%)
6. Staff radiation exposure (target: ≤1 mSv/quarter)
7. Time from order to report finalization (target: ≤48 hours)

In 2023, our center achieved a 98.3% on-time start rate and zero repeat studies for infants under 6 months—attributable to standardized preparation protocols and real-time dose calculation software integrated with the EMR.

Tracers are not merely tools—they are precision instruments calibrated to the unique biology of infancy. Their safe, effective use demands deep knowledge of developmental pharmacology, meticulous attention to dosimetry, and unwavering commitment to family-centered care. As technology evolves, our responsibility remains constant: to deliver answers without harm, clarity without compromise, and compassion without condition. Whether confirming a diagnosis of posterior urethral valves or localizing an epileptogenic focus, each tracer administered represents a carefully weighed decision—one that honors both the vulnerability and resilience of the smallest patients we serve.

For clinicians, consistent adherence to evidence-based protocols—validated by institutions like the European Association of Nuclear Medicine (EANM) Paediatric Committee and the American College of Radiology Appropriateness Criteria®—ensures reproducible outcomes. For families, transparent communication transforms anxiety into agency. And for infants, every properly administered tracer affirms a fundamental truth: that functional insight, delivered safely and precisely, is the first step toward healing.

When preparing a 2.8-kg infant for a ⁹⁹ᵐTc-DMSA scan, I calculate the dose as 1.85 MBq/kg × 2.8 kg = 5.18 MBq—then verify it against the vial assay log and cross-check with the pharmacy’s automated dose calculator. That decimal point matters—not just for image quality, but for peace of mind. Because in pediatric nuclear medicine, millibecquerels aren’t abstract units. They’re promises kept.

It’s worth noting that tracer stability is highly dependent on environmental conditions. A 2021 validation study across 12 children’s hospitals found that ⁹⁹ᵐTc-DMSA kits exposed to ambient temperatures >25°C for >2 hours showed 12–18% reduction in labeling efficiency. Hence, our protocol mandates refrigerated storage (2–8°C) and strict time limits on kit reconstitution—no more than 30 minutes before administration.

Finally, education never stops. Our team completes annual competency assessments covering radiation physics, pediatric pharmacokinetics, emergency response for extravasation (which occurs in ~0.3% of infant IV injections), and cultural humility training. Last year, we introduced Spanish- and Arabic-language video modules explaining tracer procedures—reducing pre-scan anxiety scores by 41% among non-English-speaking families.

Tracers enable us to see what cannot be seen otherwise—not just organs, but intention; not just structure, but story. In the quiet hum of the imaging suite, as the gamma camera rotates gently around a sleeping infant, what we’re really capturing is hope—measured in megabecquerels, interpreted in pixels, and delivered, always, with care.